IP Library Granted Patent US 7,504,204
Granted Patent B2
US 7,504,204 · App. 10/406,182 · Granted Mar 17, 2009

Detection of transmissible spongiform encephalopathy (TSE) protein employing a highly sensitive Western blot assay and chemiluminescent detection system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,504,204
App. No.
10/406,182
Granted
Mar 17, 2009
Kind
B2
Abstract

The invention provides a rapid, sensitive immunoassay capable of detecting and quantitating pathogenic protein to a level of 3 to 5 logs. The preferred immunoassay utilized is a chemiluminescent endpoint for a Western blot immunoassay. The invention has been successfully applied to track the clearance of pathogenic protein during production of proteins derived from plasma. It is particularly applicable and has been confirmed by bioassay to relate TSE infectivity to quantitative results on prion protein.

Claims (25)

1. An immunoassay method useful for quantitating transmissible spongiform encephalopathy (TSE) protein in a biological sample, comprising the steps of:

a) preparing a relevant biological sample for a Western blot assay, including preparing buffered dilutions of the sample using a physiologically compatible buffer and treating the buffered dilutions with proteinase-K;

b) concentrating the buffered dilutions to form concentrated proteinase-K samples;

c) preparing a spiked control sample comprising TSE protein for the Western blot assay, using a physiological compatible buffer and treating the spiked control sample with proteinase-K;

d) performing the Western blot assay for TSE protein on the concentrated proteinase-K samples and the control sample; and

e) quantitating the TSE protein results by quantifying the results of the Western blot assay by (i) determining the number of immunoreactive positions that contain a signal attributable to the presence of TSE protein in the relevant biological sample; (ii) determining the number of immunoreactive positions that contain a signal attributable to the presence of TSE protein in the control sample; and (iii) approximating the amount of TSE protein present in the relevant biological sample to the limits of detection by comparison to results obtained for the control sample,

wherein the signal attributable to the presence of TSE protein is visualized using a chemiluminescent technique, and

wherein the method can detect as low as 5 pg of TSE protein in the relevant biological sample.

2. The method of claim 1 wherein the biological sample is chosen from the group consisting of a homogenized tissue, plasma, and a plasma processing fraction sample.

3. The method of claim 1 wherein the biological sample is diluted serially, up to nine logs.

4. The method of claim 1 wherein the physiologically compatible buffer is a buffered saline solution.

5. The method of claim 4 wherein the buffer component of the buffered saline solution is chosen from the group consisting of PBS, 0.1% BSA in PBS, and Tris buffered saline.

6. The method of claim 1 wherein the buffered dilutions are concentrated by centrifugation or filtration.

7. The method of claim 1 wherein the Western blot immunoassay comprises the steps of:

a) separating the proteinase-K treated samples electrophoretically;

b) transferring the separated samples to a membrane;

c) adding a blocking agent to the membrane containing the separated samples;

d) incubating the membranes with a first antibody capable of binding to TSE protein;

e) washing the incubated membrane with a low salt buffer to remove any non-binding antibodies and proteins;

f) incubating the washed membrane with a second antibody capable of recognizing the first antibody, which second antibody contains a reporter group capable of providing a measurable signal; and

g) measuring the signal produced by counting the number of lanes with a detectable signal.

8. The method of claim 7 wherein the Western blot immunoassay utilizes the monoclonal antibody, 3F4, as the first antibody for the identification of the TSE protein on the membrane.

9. The method of claim 8 wherein the results of the Western blot are quantified by:

a) determining the number of immunoreactive lanes on the membrane that contain a signal attributable to the presence of TSE protein; and

b) approximating the amount of TSE protein present to the limits of detection.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Feb 6, 2017
From: DEUTSCHE BANK AG NEW YORK BRANK
To: GRIFOLS THERAPEUTICS INC.; GRIFOLS SHARED SERVICES NORTH AMERICA INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.
Reel/Frame 041638/0527 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193 Recorded Jan 25, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: GRIFOLS, S.A.; GRIFOLS INC.; TALECRIS BIOTHERAPEUTICS, INC.
Reel/Frame 041494/0017 →
SECURITY AGREEMENT Recorded Feb 27, 2014
From: GRIFOLS INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS-CHIRON DIAGNOSTICS CORP.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032367/0001 →
SECURITY AGREEMENT Recorded Jun 3, 2011
From: GRIFOLS, S.A.; GRIFOLS INC.; TALECRIS BIOTHERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 026390/0193 →